
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.
The company cited strategic business reasons for halting the trial, though a parallel study in non-diabetic obesity patients remains ongoing.